PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation

OBJECTIVE—: BMS-986120 is a novel first-in-class oral PAR4 (protease-activated receptor 4) antagonist with potent and selective antiplatelet effects. We sought to determine for the first time, the effect of BMS-986120 on human ex vivo thrombus formation. APPROACH AND RESULTS—: Forty healthy voluntee...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arterioscler Thromb Vasc Biol
Hauptverfasser: Wilson, Simon J., Ismat, Fraz A., Wang, Zhaoqing, Cerra, Michael, Narayan, Hafid, Raftis, Jennifer, Gray, Timothy J., Connell, Shea, Garonzik, Samira, Ma, Xuewen, Yang, Jing, Newby, David E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Lippincott Williams & Wilkins 2018
Schlagworte:
Translational Sciences
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5779320/
https://ncbi.nlm.nih.gov/pubmed/29269513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.117.310104
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge